Prometheus Biosciences comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology RAHWAY, N.J., and SAN. | April 17, 2023
Drug giant Merck, which has plants in the Triangle and Wilson, is expanding its reach with an $11 billion acquisition of San Diego-based Prometheus Biosciences.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash .
Subcutaneous infliximab achieved greater clinical remission and endoscopic response rates compared with placebo in patients with inflammatory bowel disease and has potential to become a more convenient, “patient-centric” treatment option.“Infliximab has been used in clinical practice for more than 20 years, and it is known to be one of the most effective IBD treatments,”